Loading…
www.d-pharmacy.com was cited for introducing unapproved and misbranded drugs into interstate commerce through its website, specifically opioids, benzodiazepines, and Schedule II stimulants, in violation of the Federal Food, Drug, and Cosmetic Act (sections 301(a), 301(d), 301(k), 503(b), and 505(a)). The FDA emphasized that the unlawful online sale of these controlled substances posed significant public health risks given the ongoing opioid epidemic and the high abuse potential of benzodiazepines and Schedule II stimulants, particularly when co-used with other drugs. The agency highlighted that polysubstance overdose deaths account for the vast majority of overdose deaths involving benzodiazepines, making the easy internet availability of these products especially dangerous to U.S. consumers.